{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:49:33Z","timestamp":1747151373713,"version":"3.40.5"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Reducing stroke occurrence requires the effective management of cardiovascular and other stroke risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe pre\u2010 and post\u2010stroke medication use, focusing on antithrombotic therapy and mortality risk, in individuals hospitalised for ischaemic stroke (IS) in the United Kingdom.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Using primary care electronic health records from the United Kingdom, we identified patients hospitalised for IS (July 2016\u2013September 2019) and classed them into three groups: atrial fibrillation (AF) diagnosed pre\u2010stroke, AF diagnosed post\u2010stroke, and non\u2010AF stroke (no AF diagnosed pre\u2010\/post\u2010stroke). We determined use of cardiovascular medications in the 90\u2009days pre\u2010 and post\u2010stroke and calculated mortality rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 3201 hospitalised IS cases: 76.2% non\u2010AF stroke, 15.7% AF pre\u2010stroke, and 8.1% AF post\u2010stroke. Oral anticoagulant (OAC) use increased between the pre\u2010 and post\u2010stroke periods as follows: 54.3%\u201378.7% (AF pre\u2010stroke group), 2.3%\u201384.8% (AF post\u2010stroke group), and 3.4%\u20137.3% (non\u2010AF stroke group). Corresponding increases in antiplatelet use were 30.8%\u201335.4% (AF pre\u2010stroke group) 38.5%\u201347.5% (AF post\u2010stroke group), and 37.5%\u201387.3% (non\u2010AF stroke group). Among all IS cases, antihypertensive use increased from 66.8% pre\u2010stroke to 78.8% post\u2010stroke; statin use increased from 49.6%\u201385.2%. Mortality rates per 100 person\u2010years (95% CI) were 17.30 (14.70\u201320.35) in the AF pre\u2010stroke group and 9.65 (8.81\u201310.56) among all other stroke cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings identify areas for improvement in clinical practice, including optimising the level of OAC prescribing to patients with known AF, which could potentially help reduce the future burden of stroke.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5530","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T05:54:10Z","timestamp":1661147650000},"page":"1182-1189","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre\u2010 and post\u2010stroke oral antithrombotics and mortality in patients with ischaemic stroke"],"prefix":"10.1002","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-2709","authenticated-orcid":false,"given":"Luis A.","family":"Garc\u00eda Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Pharmacoepidemiology Spanish Centre for Pharmacoepidemiologic Research (CEIFE)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gaist","sequence":"additional","affiliation":[{"name":"Research Unit for Neurology Odense University Hospital, Denmark &amp; University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanina","family":"Balabanova","sequence":"additional","affiliation":[{"name":"Integrated Evidence Generation Bayer AG  Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Brobert","sequence":"additional","affiliation":[{"name":"Integrated Evidence Generation Bayer AB  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine Population Health Research Institute McMaster University  Hamilton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-0730","authenticated-orcid":false,"given":"Luc\u00eda","family":"Cea Soriano","sequence":"additional","affiliation":[{"name":"Department of Public Health and Maternal and Child Health, Faculty of Medicine Complutense University of Madrid  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"StevensA EmmettE WangY McKevittC Wolfe CDA.The burden of stroke in Europe report.2017."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30443-3"},{"volume-title":"National Clinical Guideline for Stroke","year":"2016","key":"e_1_2_9_4_1"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040267"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.006070"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.010873"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-303472"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp12X656856"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015363"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000269"},{"key":"e_1_2_9_13_1","unstructured":"NHS. The NHS Long\u2010Term Plan. January 2019.www.longtermplan.nhs.uk"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp10X483562"},{"key":"e_1_2_9_15_1","unstructured":"THIN.The Health Improvement Network (THIN).https:\/\/www.the-health-improvement-network.com\/"},{"issue":"4","key":"e_1_2_9_16_1","first-page":"251","article-title":"Generalisability of the health improvement network (THIN) database: demographics, chronic disease prevalence and mortality rates","volume":"19","author":"Blak BT","year":"2011","journal-title":"Inform Prim Care"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317887"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031342"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195950"},{"volume-title":"Moving the Dial of Stroke Care the Sixth SSNAP Annual Report Stroke Care Received for Patients Admitted to Hospital between","author":"Kings College London Sentinel Stroke National Audit Programme","key":"e_1_2_9_20_1"},{"issue":"2","key":"e_1_2_9_21_1","first-page":"112","article-title":"Trends in preadmission oral anticoagulant use and clinical outcome in atrial fibrillation patients admitted with acute stroke in Denmark","volume":"6","author":"Larsen LK","year":"2019","journal-title":"Eur Heart J"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0171"},{"key":"e_1_2_9_23_1","first-page":"3","article-title":"Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality","volume":"7","author":"Komen JJ","year":"2019","journal-title":"Eur Heart J"},{"key":"e_1_2_9_24_1","unstructured":"National Institute of Health and Care Excellence.Cardiovascular disease: risk assessment and reduction including lipid modification. Clinical Guideline; 2014.www.nice.org.uk\/guidance\/cg181014."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5530","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T16:14:03Z","timestamp":1692634443000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/pds.5530"],"URL":"https:\/\/doi.org\/10.1002\/pds.5530","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"assertion":[{"value":"2021-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}